Featured Publications
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients
2024
Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC)
Merz L, Ito S, Walkovich K, Achebe M, Van Havre N, Frustace P, Goshua G. Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC). Blood 2024, 144: 162. DOI: 10.1182/blood-2024-202605.Peer-Reviewed Original ResearchIncremental net monetary benefitAbsolute neutrophil countWork-upBirth cohortBase-caseCenters for Medicare & Medicaid ServicesMitigate patient harmCost-effective strategyUniversal testingUS health system perspectiveThreshold sensitivity analysisDiscounted quality-adjusted life yearsInfectious work-upHealth system perspectiveNo testBone marrow biopsyIncreased risk of infectionCross-sectional studyAnti-neutrophil antibodiesDiagnostic work-upQuality-adjusted life yearsUniversal testing strategiesUnited StatesCost-effectiveMarkov cohort model